Semin Thromb Hemost 2024; 50(02): 320-324
Description of an In Vitro Platelet Function Analyzer (PFA-100/PFA-200) 30 Years in the Making
1
Department of Haematology, Sydney Centres for Thrombosis and Haemostasis, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, New South Wales, Australia
2
School of Dentistry and Medical Sciences, Faculty of Science and Health, Charles Sturt University, Wagga Wagga, New South Wales, Australia
3
School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Westmead Hospital, Westmead, New South Wales, Australia
› Institutsangaben
References
1 Advances in methods for platelet function analysis. Accessed August 30, 23 at: https://www.thieme-connect.com/products/ejournals/issue/10.1055/s-012-55744
2
Favaloro EJ.
Celebrating 50 years of Seminars in Thrombosis and Hemostasis-part I. Semin Thromb Hemost 2022; 48 (08) 871-874
3
Favaloro EJ.
Celebrating 50 years of Seminars in Thrombosis and Hemostasis-part II. Semin Thromb Hemost 2023; 49 (03) 212-216
4
Favaloro EJ.
Celebrating 50 years of Seminars in Thrombosis and Hemostasis-part III. Semin Thromb Hemost 2024; 50 (01) 4-7
5
Murano G.
The molecular structure of fibrinogen. Semin Thromb Hemost 1974; 1: 1-31
6
Neerman-Arbez M,
Casini A.
Fifty years of fibrinogen structure and function. Semin Thromb Hemost 2024; 50 (01) 148-150
7
Kundu SK,
Heilmann EJ,
Sio R,
Garcia C,
Davidson RM,
Ostgaard RA.
Description of an in vitro platelet function analyzer–PFA-100. Semin Thromb Hemost 1995; 21 (Suppl. 02) 106-112
8
Favaloro EJ.
The most highly cited publications from Seminars in Thrombosis & Hemostasis: a data analysis 50 years in the making. Semin Thromb Hemost 2024; 50 (02) 157-168
9
Kundu S,
Sio R,
Mitu A,
Ostgaard R.
Conference paper - evaluation of platelet function by PFA-100(TM). Clin Chem 1994; 40 (09) 1827-1828
10
Högman CF,
Eriksson L,
Kristensen J.
Leukocyte-depleted platelets prepared from pooled buffy coat post-transfusion increment and “in vitro bleeding time” using the Thrombostat 4000/2. Transfus Sci 1993; 14 (01) 35-39
11
Alshameeri RS,
Mammen EF.
Clinical experience with the Thrombostat 4000. Semin Thromb Hemost 1995; 21 (Suppl. 02) 1-10
12
Glaser A,
Böck M,
Rüschemeyer G.
et al.
Lagerung von Thrombozytenkonzentraten: Qualitätskontrolle durch In-vitro-Blutungstest. [Storage of thrombocyte concentrates: quality control by in vitro bleeding test] Infusionsther Transfusionsmed 1993; 20 (1–2): 14-16
13
Kristensen J,
Eriksson L,
Olsson K,
Killander A,
Högman C.
Functional capacity of transfused platelets estimated by the Thrombostat 4000/2. Eur J Haematol 1993; 51 (03) 152-155
14
Kretschmer V,
Huss B,
Weber S.
et al.
Determination of bleeding risk in thrombocytopenic patients with platelet transfusion therapy. Beitr Infusionsther Transfusionsmed 1994; 32: 434-436
15
Kretschmer V,
Huss B,
Weber S.
et al.
A contribution to the indications for platelet transfusion and determination of its therapeutic efficacy. Transfus Sci 1994; 15 (04) 361-369
16
Dietrich GV,
Kretschmer V,
Weber D,
Haupt W,
Langen B,
Huss B.
Variables influencing the Thrombostat 4000: recommended standardization. Semin Thromb Hemost 1995; 21 (Suppl. 02) 11-19
17
Söhngen D,
Hattstein E,
Heyll A,
Meckenstock G,
Wienen S,
Schneider W.
Hematological parameters influencing the Thrombostat 4000. Semin Thromb Hemost 1995; 21 (Suppl. 02) 20-24
18
Kratzer MA,
Negrescu EV,
Hirai A,
Yeo YK,
Franke P,
Siess W.
The Thrombostat system. A useful method to test antiplatelet drugs and diets. Semin Thromb Hemost 1995; 21 (Suppl. 02) 25-31
19
Beck KH,
Mohr P,
Bleckmann U,
Schweer H,
Kretschmer V.
Desmopressin effect on acetylsalicylic acid impaired platelet function. Semin Thromb Hemost 1995; 21 (Suppl. 02) 32-39
20
Beck KH,
Bleckmann U,
Mohr P,
Kretschmer V.
DDAVP's shortening of the bleeding time seems due to plasma von Willebrand factor. Semin Thromb Hemost 1995; 21 (Suppl. 02) 40-43
21
Weippert-Kretschmer M,
Witte M,
Budde U,
Vigh T,
Kretschmer V,
Scharrer I.
The Thrombostat 4000. A sensitive screening test for von Willebrand's disease. Semin Thromb Hemost 1995; 21 (Suppl. 02) 44-51
22
Ulshöfer B,
Dorst V,
Kretschmer V,
Köhl H,
Riedmiller H.
Hemostaseological management of urological operations in patients taking aspirin using the Thrombostat 4000. Semin Thromb Hemost 1995; 21 (Suppl. 02) 52-58
23
Aleskog AE,
Killander A,
Olsson K,
Eriksson L,
Kristensen J.
Preoperative evaluation of primary hemostasis in patients with thrombocytopenia using the Thrombostat 4000. Semin Thromb Hemost 1995; 21 (Suppl. 02) 59-65
24
Tabuchi N,
Tigchelaar I,
van Oeveren W.
Shear-induced pathway of platelet function in cardiac surgery. Semin Thromb Hemost 1995; 21 (Suppl. 02) 66-70
25
Tigchelaar I,
Monnink SH,
Haan J,
Tabuchi N,
van Oeveren W.
Platelet function analysis after in vitro treatment with hemostasis-affecting components. Semin Thromb Hemost 1995; 21 (Suppl. 02) 71-76
26
Dietrich GV,
Söhngen D,
Kretschmer V.
Therapeutic use of phospholipids in thrombocytopenic or thrombocytopathic patients. Semin Thromb Hemost 1995; 21 (Suppl. 02) 77-78
27
Kretschmer V,
Huss B,
Bonacker G.
et al.
Thrombocytopenia-adapted in vitro bleeding test assesses platelet function in thrombocytopenic patients. Semin Thromb Hemost 1995; 21 (Suppl. 02) 79-90
28
Böck M,
Groh J,
Glaser A,
Storck K,
Kratzer MA,
Heim MU.
Quality control of platelet concentrates by the Thrombostat 4000. Semin Thromb Hemost 1995; 21 (Suppl. 02) 91-95
29
Kretschmer V,
Huss B,
Feller K,
Ponath N,
Kiefel V.
Influence of HPA-1a and HLA antibodies on primary hemostasis. Semin Thromb Hemost 1995; 21 (Suppl. 02) 96-102
30
Suzuki S,
Matsuno K,
Kondoh M.
Primary hemostasis during women's life cycle measured by Thrombostat 4000. Semin Thromb Hemost 1995; 21 (Suppl. 02) 103-105
31
Mammen EF,
Alshameeri RS,
Comp PC.
Preliminary data from a field trial of the PFA-100 system. Semin Thromb Hemost 1995; 21 (Suppl. 02) 113-121
32
Kratzer MAA,
Kretschmer V,
Mammen EF.
Advances in methods for platelet function analysis. Semin Thromb Hemost 1995
33
Mammen EF,
Comp PC,
Gosselin R.
et al.
PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998; 24 (02) 195-202
34
Favaloro EJ.
Clinical utility of the PFA-100. Semin Thromb Hemost 2008; 34 (08) 709-733
35
Favaloro EJ,
Kessler C,
Levi M.
Editorial. Eberhard Mammen 1930–2008. Semin Thromb Hemost 2008; 34: 307
36
Favaloro EJ.
A tribute to Eberhard F. Mammen, M.D. (1930-2008). Semin Thromb Hemost 2008; 34 (08) 703-707
37
Favaloro EJ,
Pasalic L,
Lippi G.
Towards 50 years of platelet function analyser (PFA) testing. Clin Chem Lab Med 2022; 61 (05) 851-860
38
Gosselin RC.
From ink pens to computers: a personal look back at landmark changes during 5 decades as a clinical laboratory scientist in U.S. hemostasis laboratories. Semin Thromb Hemost 2023; 49 (03) 225-233
39
Favaloro EJ.
Evolution of hemostasis testing: a personal reflection covering over 40 years of history. Semin Thromb Hemost 2023;
40
Favaloro EJ,
Bonar R.
External quality assessment/proficiency testing and internal quality control for the PFA-100 and PFA-200: an update. Semin Thromb Hemost 2014; 40 (02) 239-253
41
Favaloro EJ,
Facey D,
Henniker A.
Use of a novel platelet function analyzer (PFA-100) with high sensitivity to disturbances in von Willebrand factor to screen for von Willebrand's disease and other disorders. Am J Hematol 1999; 62 (03) 165-174
42
Favaloro EJ.
Utility of the platelet function analyser (PFA-100/200) for exclusion or detection of von Willebrand disease: a study 22 years in the making. Thromb Res 2020; 188: 17-24
43
Favaloro EJ,
Kershaw G,
Bukuya M,
Hertzberg M,
Koutts J.
Laboratory diagnosis of von Willebrand disorder (vWD) and monitoring of DDAVP therapy: efficacy of the PFA-100 and vWF:CBA as combined diagnostic strategies. Haemophilia 2001; 7 (02) 180-189
44
Leal-Noval SR,
Casado M,
Palomares C.
et al.
Prospective assessment of platelet function in patients undergoing elective resection of glioblastoma multiforme. Platelets 2023; 34 (01) 2216802
45
Kennerly R,
Coleman AE,
Jasper SL,
Arnold RD,
Brainard BM.
Effects of orally administered pimobendan on platelet function in healthy adult cats. Am J Vet Res 2023; 84 (09) ajvr.23.05.0103
46
Vettori M,
Carpenè G,
Salvagno GL.
et al.
Effects of recombinant SARS-CoV-2 spike protein variants on platelet morphology and activation. Semin Thromb Hemost 2024; 50 (02) 275-283
47
Eckart F,
Tauer JT,
Suttorp M,
Knöfler R.
Impact of tyrosine kinase inhibitors applied for first-line chronic myeloid leukemia treatment on platelet function in whole blood of healthy volunteers in vitro. Hamostaseologie 2023; 43 (03) 179-187
48
Sukun A,
Tekeli F.
Comparison of clopidogrel, prasugrel and ticagrelor response of patients by PFA-100-innovance test results. Indian J Hematol Blood Transfus 2023; 39 (02) 294-299
49
Büchsel M,
Geisen U,
Beckenkamp C.
et al.
The effect of recombinant versus plasma-derived von Willebrand factor on prolonged PFA closure times in ECMO patients with acquired von Willebrand syndrome - an observational study. Thromb J 2023; 21 (01) 4
50
Davidson S.
Monitoring of antiplatelet therapy. Methods Mol Biol 2023; 2663: 381-402
51
Belkacemi M,
Berber A.
Platelet dysfunction in blood donors detected by platelet function analyzer PFA-100™. Cureus 2022; 14 (05) e25497
52
Llobet D,
Vallvé C,
Tirado I.
et al.
Platelet hyperaggregability and venous thrombosis risk: results from the RETROVE project. Blood Coagul Fibrinolysis 2021; 32 (02) 122-131
